Botanical compound has wound-healing applications
healing applications of its proprietary herbal extract compound
WD-667 hit the market in the next two months.
Nutra Pharma of the US says it expects to see the first four wound healing applications of its proprietary herbal extract compound WD-667 hit the market in the next two months.
The company's joint venture partner, Terra BioPharma, will manufacture the raw product, which will then be shipped to a manufacturing facility in the United States for final product development, manufacture and distribution, according to Dr Rafael Gonzales-Vizoso, chief science officer and medical director of Nutra Pharma.
"Nutra Pharma plans to fully develop, after obtaining appropriate patent protection, products from the compound in which all of the indications have so far been proven effective, while continuing research and development into possible further uses, as well as the basic chemistry, mechanism of action and effects at both the cellular and molecular level of the compound," he said.
"We are seeking to fully develop the applications for which we have conclusive evidence that the compound works, some of which could have a short development period, since the WD-667 has proven safe and effective and no side effects have been noted either when applied topically or taken internally," Dr Gonzales-Vizoso continued.
"Furthermore, the wound healing devices incorporating WD-667 may qualify for FDA 510k classification or a 510k exemption. Qualifying for this classification would significantly diminish WD-667's development time. We are also in early discussions with different product development and manufacturing companies, to start strategic alliances for the final development and commercialisation of our products."
Nutra Pharma develops proprietary technologies for the manufacture of complex medicinal botanical extracts.
